PE22-28 · PE 22-28
PE-22-28 is a synthetic heptapeptide fragment derived from the neuroprotective protein Prohibitin (PHB). It was identified through screening of PHB-derived peptide fragments for anti-aging properties at the cellular level. PE-22-28 enhances cellular stress resistance and has been studied in the context of neuroprotection, anti-aging, and cognitive preservation. It is one of the newer nootropic peptides with limited but intriguing preclinical data.
Any time of day. No fasting required. Often combined with other nootropics.
Start here. Every protocol below is ordered lowest-first. Begin at the smallest effective dose, hold about a week to assess tolerance, and step up only if needed.
PE-22-28 derived from Prohibitin interacts with mitochondrial and nuclear signaling pathways to enhance cellular stress resistance. PHB family proteins are involved in mitochondrial morphogenesis, cell cycle regulation, and transcriptional control. The exact receptor target and signaling pathway for PE-22-28 specifically is less well-characterized than many other peptides in this database.
Days 1-14: Minimal changes.
Weeks 2-6: Possible cognitive improvements.
Weeks 6+: Cumulative neuroprotective effects.
Each reference below was re-fetched from its PubMed record, and the quoted sentence was confirmed to appear in that abstract and to support the claim it sits under. Follow any of them to read the source.
From the study of spadin blood degradation products, we designed a 7 amino-acid peptide, PE 22-28.
From the study of spadin blood degradation products, we designed a 7 amino-acid peptide, PE 22-28.
Evidence scope. Rodent/preclinical spadin-analog work; no human dosing or safety evidence.
Claims we could not support
No abstract we checked supports these for this molecule at this route. That is not the same as saying they are false — it marks where the evidence is missing.
Dose/route: 500 mcg to 1 mg daily via SubQ injection, Daily. No checked live PubMed abstract supported this complete molecule/formulation/route/dose/frequency combination.
Primary safety claim: Limited data. No checked live abstract directly established this as the primary concern for the card's exact formulation and regimen.
Anti-aging nootropic
Prohibitin-derived. Preclinical data supports cellular stress resistance. Very early stage research.
Two different questions: what is documented about running these together, and what is documented about drawing them into the same syringe. A good pharmacological partner can still have to be pinned separately.
Check any specific pair in the Stack & Interaction Checker, which answers both questions separately. Absence of a documented conflict is not evidence of safety.
SubQ
Cellular stress resistance signaling
Enzymatic degradation (peptidases)
Storage. Standard BAC water 2-8C. 28 days.
Research compound only. Not FDA-approved.
Put it to work
Open PE-22-28 straight into OnePin with your vial and dose pre-filled, then let it handle the syringe math and remind you before the vial runs out.
Open PE-22-28 in the app →Go deeper
The complete PE-22-28 walkthrough, real protocol discussion and coaching live inside the BlessUp community on Skool.
Join the community ↗Track it in OnePin. Log vials, draws, and protocols in the app.
Type a name, brand, or tool. Esc closes.